JMDSJournal of Medicines Development Sciences2382-63632382-6371WHIOCE PUBLISHING PTE. LTD.10.18063/jmds.v1i1.121Review ArticleTransCelerate: a global collaboration across biophar-maceutical R&D to accelerate and simplify new medi-cines developmenhttps://artdesignp.com/journal/JMDS/1/1/10.18063/jmds.v1i1.121MarksLynn2015112015-07-16The European Lead Factory (ELF) is a unique collaborative public–private partnership aiming to deliver innovative drug discovery starting points and improving the value generated by ultra-High Throughput Screening (uHTS) approaches. Composed of a unique compound collection derived from private pharmaceutical company collections and complemented with new chemistries from a unique public collection, it offers a unique uHTS platform accessible to both private companies and publicly funded researchers. One of the key challenges in setting up ELF has been to balance access to screening results with protecting the value of compounds in the collection. Through an ‘honest data broker’ data management platform and a royalty reward scheme based on achieved milestones, ELF has been able to overcome these challenges. Set up in 2013, it has already accepted 42 targets for screening, submitted by publicly funded researchers, and generated 12 Qualified Hit Lists. In addition, 55,000 new library compounds have been generated by the public partners and added to the 320,000 compounds made available by the companies. Although it faced many challenges in becoming operational, this unique experiment in collaboration is already generating exciting results that will hopefully, eventually lead to better medicines and tools to advance our biological knowledge, and should act as a template for future approaches in the area.drug discovery, public–private partnership, ultra-high throughput screening, biological targets, chemistry scaffolds, honest data broker, qualified hit list, European Screening Centre, biomedical innovation, Joint European Compound Collection

1. AbbVie. n.d. Viewed April 2, 2015. <http://www.abbvie.com/>.2. Actavis + Allergan. n.d. Viewed April 2, 2015. <http://www.allergan.com/index.htm>.3. Amgen. n.d. Viewed May 26, 2015. <http://www.amgen.com>.4. AstraZeneca. n.d. Viewed April 2, 2015. <http://www.astrazeneca.com/Home>.5. Astellas Pharma US. n.d. Viewed April 2, 2015. <http://www.astellas.us/>.6. Biogen. n.d. Viewed April 2, 2015. <https://www.biogen.com/>.7. Boehringer Ingelheim. n.d. Viewed April 2, 2015. <http://www.boehringer-ingelheim.com/>.8. Bristol-Myers Squibb. n.d. Viewed April 2, 2015. <http://www.bms.com/pages/default.aspx>.9. EMD Serono, Inc. n.d. Viewed April 2, 2015. <http://www.emdserono.com/en/index.html;jsessionid=3CCD32E27E5C85E67BB06FC590F9D73A>.10. GlaxoSmithKline. n.d. Viewed April 2, 2015. <https://www.gsk.com/>.11. Johnson & Johnson. n.d. Viewed April 2, 2015. <http://www.jnj.com/>.12. Eli Lilly and Company. n.d. Viewed April 2, 2015. <http://www.lilly.com/Pages/Home.aspx>.13. Medgenics. n.d. Viewed April 2, 2015. <http://www.medgenics.com/index.php>.14. Merck & Co. n.d. Viewed April 2, 2015. <http://www.merck.com/index.html>.15. Novo Nordisk. n.d. Viewed April 2, 2015. <http://novonordisk-us.com/documents/home_page/document/index.asp>.16. Pfizer. n.d. Viewed April 2, 2015. <http://www.pfizer.com/>.17. Roche. n.d. Viewed April 2, 2015. <http://www.roche.com/index.htm>.18. Sanofi. n.d. Viewed April 2, 2015. <http://www.sanofi.us/l/us/en/index.jsp>.19. Shionogi. n.d. Viewed April 2, 2015. <http://www.shionogi.com/>.20. UCB Pharma. n.d. Viewed April 2, 2015. <http://www.ucb-usa.com/Home>.21. Tufts Center for the Study of Drug Development. Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion. November 18, 2014. Viewed June 1, 2015. <http://csdd.tufts.edu/news/complete_story/pr_tufts_csd_2014_cost_study>.22. TransCelerate BioPharma Inc. Clinical Data Standards. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/clinical-data-standards/>.23. TransCelerate BioPharma Inc. Site Qualification and Training (SQT). n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/site-qualification-and-training-sqt/>.24. TransCelerate BioPharma Inc. Risk-Based Monitoring. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/risk-based-monitoring/>.25. TransCelerate BioPharma Inc. Clinical Data Standards. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/clinical-data-standards/>.26. Clinical Data Interchange Standards Consortium (CDISC). n.d. Viewed April 27, 2015. <http://www.cdisc.org/>.27. Critical Path Institute. n.d. Viewed May 29, 2015. <http://c-path.org/>.28. National Cancer Institute – Enterprise Vocabulary Service. n.d. Viewed May 29, 2015. <http://evs.nci.nih.gov/>.29. Food and Drug Administration. n.d. Viewed May 29, 2015. <http://www.fda.gov/>.30. Coalition for Accelerating Standards and Therapies (CFAST). n.d. Viewed April 27, 2015. <http://c-path.org/programs/cfast/>.31. TransCelerate BioPharma Inc. Comparator Drugs. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/comparator-network/>.32. TransCelerate BioPharma Inc. Shared Investigator Platform. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/shared-investigator-platform/>.33. TransCelerate BioPharma Inc. Risk-Based Monitoring. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/risk-based-monitoring/>.34. TransCelerate BioPharma Inc. RBM's Volume 3 Monitoring Update. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/wp-content/uploads/2014/11/TransCelerate-RBM-Update-Volume-II-FINAL-17NOV2014.pdf>.35. TransCelerate BioPharma Inc. Site Qualification and Training (SQT). n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/site-qualification-and-training-sqt/>.36. TransCelerate BioPharma Inc. GCP Training Mutual Recognition. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/assets/site-qualification-and-training/>.37. ICH. The Principles of ICH GCP. n.d. Viewed June 1, 2015. <http://ichgcp.net/2-the-principles-of-ich-gcp-2>.38. TransCelerate BioPharma Inc. GCP Training Minimum Criteria. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/wp-content/uploads/2013/10/TransCelerate-GCP-Training-Minimum-Criteria-in-Operating-Principles_0.pdf>.39. TransCelerate BioPharma Inc. GCP Training Mutual Recognition. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/gcp-training-attestation/#headline6>.40. Institute of Medicine of the National Academies. "Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk". January 2015. Viewed April 27, 2015. <http://www.nap.edu/openbook.php?record_id=18998>.41. TransCelerate BioPharma Inc. Clinical Data Standards. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/clinical-data-standards/>.42. TransCelerate BioPharma Inc. Shared Investigator Platform. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/shared-investigator-platform/>.43. TransCelerate BioPharma Inc. Placebo/Standard of Care Data-Sharing. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/placebo-standard-of-care/>.44. TransCelerate BioPharma Inc. Clinical Data Transparency. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/initiatives/clinical-data-transparency/>.45. TransCelerate BioPharma Inc. elabels. n.d. Viewed May 26, 2015. <http://www.transceleratebiopharmainc.com/initiatives/elabels/>.46. Applied Clinical Trials. TransCelerate’s eLabeling Initiative. April 22, 2015. Viewed June 3, 2015. <http://www.appliedclinicaltrialsonline.com/transcelerate-s-elabeling-initiative>.47. Deloitte. Beyond M&A: Alternative arrangements appear to be reshaping the life sciences landscape. n.d. Viewed May 26, 2015. <http://blogs.deloitte.com/centerforhealthsolutions/2015/04/beyond-ma-alternative-arrangements-appear-to-be-reshaping-the-life-sciences-landscape.html?id=us%3A2-sm%3A3tw%3Achsblog%3Aeng%3Achs%3A043015%3Adeloittehealth%3A042715#.VWX3D5PzkpW>.48. TransCelerate BioPharma Inc. Strategic Priorities. n.d. Viewed April 27, 2015. <http://www.transceleratebiopharmainc.com/about/brand/>.